GHK-CU 50 mg

GHK-Cu is a copper-binding tripeptide that has been studied for its roles in matrix remodeling, inflammation regulation, tissue repair, and angiogenesis. In dermatological research, it has been investigated for potential effects on collagen synthesis and skin remodeling.

Preclinical data consistently support these effects, but the clinical evidence remains sparse and does not meet contemporary active-entity quality standards. GHK-Cu should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated drug.

Published dermatology studies report injection site reactions in 8–15% of participants, including erythema, mild edema, and temporary discomfort lasting 1–3 days. Systemic adverse events remain rare in available trials, though long-term safety data in non-dermatology populations is sparse.

Some animal and early-phase studies noted elevated inflammatory cytokines at higher doses, though clinical relevance in humans at therapeutic doses remains unclear. Allergic sensitization to copper compounds has been reported anecdotally but is not well-characterized.

Research and clinical literature typically references GHK-Cu protocols in the range of 0.5–3 mg administered via subcutaneous injection, with frequency varying between weekly and monthly. These ranges are provided for educational reference only and do not constitute dosing guidance.

GHK-Cu is not an FDA-approved human pharmaceutical product, and injectable GHK-Cu is not on the 503A Bulks List. The safety and efficacy of injectable GHK-Cu have not been established through controlled clinical trials.

Injectable GHK-Cu has never had clear FDA authorization for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, and is not on the formal 503A Bulks List. Topical formulations have historically had a more permissive regulatory position. The FDA is expected to evaluate injectable GHK-Cu through the PCAC process in 2027.

Regulatory status can vary, and individuals should consult appropriate legal or regulatory resources for current information.

GHK-CU 50 mg contains the copper peptide GHK-Cu in lyophilized powder form. It is supplied for research and educational purposes. In research contexts, GHK-Cu has been studied for matrix remodeling, tissue repair, and related biological activities.

It is not an FDA-approved human pharmaceutical product and is not intended for human use outside approved research contexts.

Frequency of use depends on the specific research or clinical context. In available literature, GHK-Cu protocols are typically referenced as weekly or monthly injections. These frequencies are for educational reference only and do not constitute dosing guidance.

Reconstitution and handling procedures should follow the guidelines provided with the specific product.

Post-cycle therapy is not applicable to GHK-Cu, as it is not a compound that suppresses the hypothalamic-pituitary-gonadal axis. It is a copper peptide studied for tissue repair and matrix remodeling.

When GHK-Cu is used as part of a broader research protocol that includes anabolic compounds, standard PCT protocols such as those involving Clomixyl or Nolvaxyl would be relevant to those compounds, not to GHK-Cu itself.

GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). It has been studied for its roles in matrix remodeling, inflammation regulation, redox balance, angiogenesis, and tissue repair. It is thought to act as a signaling molecule that modulates gene expression related to collagen synthesis and extracellular matrix remodeling.

Preclinical data support these effects, but clinical evidence remains sparse.

The time required to observe effects depends on the specific outcome being evaluated, the research or clinical context, and individual factors. In dermatological studies, some changes have been reported over weeks to months.

However, the clinical evidence for GHK-Cu remains limited, and the time to effect is not well characterized through controlled clinical research.

GHK-Cu is one of the most extensively studied copper peptides, but the literature frequently treats GHK-Cu as a single active ingredient despite formulation-dependent variation in coordination state, speciation, stability, and pharmacokinetics. There is no single copper peptide that is universally best.

The appropriate choice depends on the specific research or clinical context.

GHK-CU 50 mg contains the copper peptide GHK-Cu, which is studied for matrix remodeling and tissue repair through copper-dependent signaling pathways. BPC 157 5 mg is a different peptide studied for gastrointestinal and tissue repair properties through different mechanisms.

These are different compounds with different research profiles.

The milligram strength of the vial (50 mg) refers to the total amount of GHK-Cu in the vial, not the amount administered per dose. The dose administered depends on how the powder is reconstituted and the specific protocol being followed.

It is important to distinguish vial strength from administered dose. A 50 mg vial can be reconstituted with an appropriate volume of diluent to achieve the desired concentration for research or educational purposes.